Synergy Pharmaceuticals to Present Data on SP-333 at Digestive Disease Week
Digestive Disease Week 2014
NEW YORK -- May 1, 2014
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that updated
preclinical data on the company’s second-generation uroguanylin analog,
SP-333, will be presented during a poster session at Digestive Disease Week
(DDW) in Chicago, May 3 - May 6, 2014.
The following poster will be presented at DDW on Saturday, May 3, 2014, 8am –
5pm in McCormick Place - South Hall:
Oral Treatment with SP-333, an Agonist of Guanylate Cyclase-C, Dramatically
Ameliorates Methadone-Induced Bowel Dysfunction in Rats (Palejwala, Vaseem A.;
Saykhedkar, Sayali; Joshi, Apoorva; Patwa, Viren; Vemalapally, Laxmi; Thadi,
Anusha; Foss, John A.; Shailubhai, Kunwar ^ - Poster #Sa2013)
SP-333 is Synergy’s second-generation uroguanylin analog in development to
treat patients with opioid-induced constipation (OIC) and ulcerative colitis
(UC). SP-333 is a synthetic analog of the naturally occurring gastrointestinal
hormone, uroguanylin, designed as a highly stable and potent peptide that is
resistant to proteolysis in gastric and intestinal fluids. SP-333 has
successfully completed phase I single and multiple ascending dose studies in
healthy volunteers and is currently in a phase 2 clinical trial for OIC.
Synergy is also developing a unique formulation of SP-333 for treating GI
inflammation in patients with UC. For more information, please visit
Synergy Pharmaceuticals Inc.
Press spacebar to pause and continue. Press esc to stop.